{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:18:10Z","timestamp":1780960690155,"version":"3.54.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T00:00:00Z","timestamp":1515801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40262-017-0623-4","type":"journal-article","created":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T10:19:11Z","timestamp":1515838751000},"page":"797-816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides"],"prefix":"10.1007","volume":"57","author":[{"given":"Valentin","family":"al Jalali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,13]]},"reference":[{"key":"623_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/491709","volume":"42","author":"DP Levine","year":"2006","unstructured":"Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42:S5\u201312.","journal-title":"Clin Infect Dis"},{"key":"623_CR2","first-page":"w14339","volume":"146","author":"F Olearo","year":"2016","unstructured":"Olearo F, Albrich WC, Vernaz N, Harbarth S, Kronenberg A, Swiss Centre For Antibiotic Resistance Anresis. Staphylococcus aureus and methicillin resistance in Switzerland: regional differences and trends from 2004 to 2014. Swiss Med Wkly. 2016;146:w14339.","journal-title":"Swiss Med Wkly"},{"key":"623_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12879-017-2271-6","volume":"17","author":"J Walter","year":"2017","unstructured":"Walter J, Noll I, Feig M, Weiss B, Claus H, Werner G, et al. Decline in the proportion of methicillin resistance among Staphylococcus aureus isolates from non-invasive samples and in outpatient settings, and changes in the co-resistance profiles: an analysis of data collected within the Antimicrobial Resistance Sur. BMC Infect Dis. 2017;17:169.","journal-title":"BMC Infect Dis"},{"key":"623_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1086\/499367","volume":"42","author":"RM Klevens","year":"2006","unstructured":"Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992\u20132003. Clin Infect Dis. 2006;42:389\u201391.","journal-title":"Clin Infect Dis"},{"key":"623_CR5","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1086\/499404","volume":"42","author":"LC McDonald","year":"2006","unstructured":"McDonald LC. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis. 2006;42:S65\u201371.","journal-title":"Clin Infect Dis"},{"key":"623_CR6","volume-title":"Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2017","unstructured":"European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017."},{"key":"623_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3201\/eid1302.060781","volume":"13","author":"CL Maree","year":"2007","unstructured":"Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis. 2007;13:236\u201342.","journal-title":"Emerg Infect Dis"},{"key":"623_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa043252","volume":"352","author":"SK Fridkin","year":"2005","unstructured":"Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436\u201344.","journal-title":"N Engl J Med"},{"key":"623_CR9","doi-asserted-by":"publisher","first-page":"e0136082","DOI":"10.1371\/journal.pone.0136082","volume":"10","author":"S Zhang","year":"2015","unstructured":"Zhang S, Sun X, Chang W, Dai Y, Ma X. Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. PLoS One. 2015;10:e0136082.","journal-title":"PLoS One"},{"key":"623_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1086\/527392","volume":"46","author":"DM Sievert","year":"2008","unstructured":"Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-Resistant Staphylococcus aureus in the United States, 2002\u20132006. Clin Infect Dis. 2008;46:668\u201374.","journal-title":"Clin Infect Dis"},{"key":"623_CR11","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1001\/jama.1993.03510150030010","volume":"270","author":"From the Centers for Disease Control and Prevention","year":"1993","unstructured":"From the Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin\u2014United States, 1989-1993. JAMA. 1993;270:1796.","journal-title":"JAMA"},{"key":"623_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.7164\/antibiotics.37.615","volume":"37","author":"A Borghi","year":"1984","unstructured":"Borghi A, Coronelli C, Faniuolo L, Allievi G, Pallanza R, Gallo GG. Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin). J Antibiot (Tokyo). 1984;37:615\u201320.","journal-title":"J Antibiot (Tokyo)"},{"key":"623_CR13","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1016\/j.bmcl.2003.08.067","volume":"13","author":"JK Judice","year":"2003","unstructured":"Judice JK, Pace JL. Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett. 2003;13:4165\u20138.","journal-title":"Bioorg Med Chem Lett"},{"key":"623_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7164\/antibiotics.57.326","volume":"57","author":"MR Leadbetter","year":"2004","unstructured":"Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo). 2004;57:326\u201336.","journal-title":"J Antibiot (Tokyo)"},{"key":"623_CR15","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1093\/cid\/civ522","volume":"61","author":"E Wenzler","year":"2015","unstructured":"Wenzler E, Rodvold KA. Telavancin: the long and winding road from discovery to Food and Drug Administration approvals and future directions. Clin Infect Dis. 2015;61:S38\u201347.","journal-title":"Clin Infect Dis"},{"key":"623_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/cid\/civ311","volume":"61","author":"LD Saravolatz","year":"2015","unstructured":"Saravolatz LD, Stein GE. Oritavancin: a long-half-life lipoglycopeptide. Clin Infect Dis. 2015;61:627\u201332.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"623_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/23744235.2017.1296968","volume":"49","author":"RP Dash","year":"2017","unstructured":"Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis (Lond). 2017;49(7):483\u201392. https:\/\/doi.org\/10.1080\/23744235.2017.1296968 .","journal-title":"Infect Dis (Lond)."},{"key":"623_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","volume":"49","author":"DL Higgins","year":"2005","unstructured":"Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:1127\u201334.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR19","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1128\/AAC.05403-11","volume":"56","author":"Y Song","year":"2012","unstructured":"Song Y, Lunde CS, Benton BM, Wilkinson BJ. Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies. Antimicrob Agents Chemother. 2012;56:3157\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR20","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1128\/AAC.00714-11","volume":"55","author":"F Lebreton","year":"2011","unstructured":"Lebreton F, Depardieu F, Bourdon N, Fines-Guyon M, Berger P, Camiade S, et al. d-Ala-d-Ser VanN-type transferable vancomycin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 2011;55:4606\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1590\/0074-0276140019","volume":"109","author":"M Sun","year":"2014","unstructured":"Sun M, Wang Y, Chen Z, Zhu X, Tian L, Sun Z. The first report of the vanC1 gene in Enterococcus faecium isolated from a human clinical specimen. Mem Inst Oswaldo Cruz. 2014;109:712\u20135.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"623_CR22","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1128\/AAC.01737-09","volume":"54","author":"CM Hill","year":"2010","unstructured":"Hill CM, Krause KM, Lewis SR, Blais J, Benton BM, Mammen M, et al. Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin. Antimicrob Agents Chemother. 2010;54:2814\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0738-1751(90)90027-A","volume":"7","author":"S Dutka-Malen","year":"1990","unstructured":"Dutka-Malen S, Courvalin P. Update on glycopeptide resistance in enterococci. Antimicrob Newsl. 1990;7:81\u20136.","journal-title":"Antimicrob Newsl"},{"key":"623_CR24","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1128\/AAC.01641-07","volume":"52","author":"DC Draghi","year":"2008","unstructured":"Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:2383\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR25","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1128\/jb.178.5.1302-1309.1996","volume":"178","author":"S Evers","year":"1996","unstructured":"Evers S, Courvalin P. Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583. J Bacteriol. 1996;178:1302\u20139.","journal-title":"J Bacteriol"},{"key":"623_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ijmm.2004.10.002","volume":"294","author":"P Courvalin","year":"2005","unstructured":"Courvalin P. Genetics of glycopeptide resistance in Gram-positive pathogens. Int J Med Microbiol. 2005;294:479\u201386.","journal-title":"Int J Med Microbiol"},{"key":"623_CR27","first-page":"549","volume":"138","author":"I Praharaj","year":"2013","unstructured":"Praharaj I, Sujatha S, Parija SC. Phenotypic & genotypic characterization of vancomycin resistant Enterococcus isolates from clinical specimens. Indian J Med Res. 2013;138:549\u201356.","journal-title":"Indian J Med Res"},{"key":"623_CR28","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1128\/JCM.35.12.3166-3170.1997","volume":"35","author":"B Toye","year":"1997","unstructured":"Toye B, Shymanski J, Bobrowska M, Woods W, Ramotar K. Clinical and epidemiologic significance of enterococci intrinsically resistant to vancomycin (possessing the vanC genotype). J Clin Microbiol. 1997;35:3166\u201370.","journal-title":"J Clin Microbiol"},{"key":"623_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/mdr.2013.0108","volume":"20","author":"C H\u00f6lzel","year":"2014","unstructured":"H\u00f6lzel C, Bauer J, Stegherr E-M, Schwaiger K. Presence of the vancomycin resistance gene cluster vanC1, vanXYc, and vanT in Enterococcus casseliflavus. Microb Drug Resist. 2014;20:177\u201380.","journal-title":"Microb Drug Resist"},{"key":"623_CR30","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1128\/AAC.36.9.2005","volume":"36","author":"R Leclercq","year":"1992","unstructured":"Leclercq R, Dutka-Malen S, Duval J, Courvalin P. Vancomycin resistance gene vanC is specific to Enterococcus gallinarum. Antimicrob Agents Chemother. 1992;36:2005\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1128\/AAC.00908-07","volume":"52","author":"W Zhu","year":"2008","unstructured":"Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB. Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-Like vanA plasmids in Michigan. Antimicrob Agents Chemother. 2008;52:452\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"623_CR32","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1086\/491711","volume":"42","author":"P Courvalin","year":"2006","unstructured":"Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006;42(Suppl 1):S25\u201334.","journal-title":"Clin Infect Dis"},{"key":"623_CR33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/jac\/dkl235","volume":"58","author":"KD Leuthner","year":"2006","unstructured":"Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58:338\u201343.","journal-title":"J Antimicrob Chemother"},{"key":"623_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00228-015-1847-6","volume":"71","author":"PD Worboys","year":"2015","unstructured":"Worboys PD, Wong SL, Barriere SL. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015;71:707\u201314.","journal-title":"Eur J Clin Pharmacol"},{"key":"623_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40261-015-0340-4","volume":"35","author":"PJ Scoble","year":"2015","unstructured":"Scoble PJ, Owens RC, Puttagunta S, Yen M, Dunne MW. Pharmacokinetics, safety, and tolerability of a single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy Japanese subjects. Clin Drug Investig. 2015;35:785\u201393.","journal-title":"Clin Drug Investig"},{"key":"623_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1128\/AAC.49.1.148-152.2005","volume":"49","author":"GJ Fetterly","year":"2005","unstructured":"Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3\u00a0days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005;49:148\u201352.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/AAC.32.1.92","volume":"32","author":"M Boeckh","year":"1988","unstructured":"Boeckh M, Lode H, Borner K, Hoffken G, Wagner J, Koeppe P. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother. 1988;32:92\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR38","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1128\/AAC.26.6.881","volume":"26","author":"L Verbist","year":"1984","unstructured":"Verbist L, Tjandramaga B, Hendrickx B, Van Hecken A, Van Melle P, Verbesselt R, et al. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother. 1984;26:881\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR39","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1128\/AAC.01750-09","volume":"54","author":"J-P Shaw","year":"2010","unstructured":"Shaw J-P, Cheong J, Goldberg MR, Kitt MM. Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. Antimicrob Agents Chemother. 2010;54:3365\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/AAC.00875-07","volume":"52","author":"MH Gotfried","year":"2008","unstructured":"Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008;52:92\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/0091270008330162","volume":"49","author":"T Marbury","year":"2009","unstructured":"Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49:465\u201376.","journal-title":"J Clin Pharmacol"},{"key":"623_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/bdd.2510130307","volume":"13","author":"GA Thompson","year":"1992","unstructured":"Thompson GA, Smithers JA, Kenny MT, Dulworth JK, Kulmala HK, Yuh L, et al. Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers. Biopharm Drug Dispos. 1992;13:213\u201320.","journal-title":"Biopharm Drug Dispos"},{"key":"623_CR43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1128\/AAC.31.3.393","volume":"31","author":"DP Healy","year":"1987","unstructured":"Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother. 1987;31:393\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1046\/j.1365-2125.1998.00805.x","volume":"46","author":"M Brunner","year":"1998","unstructured":"Brunner M, Schmiedberger A, Schmid R, J\u00e4ger D, Piegler E, Eichler HG, et al. Direct assessment of peripheral pharmacokinetics in humans: comparison between cantharides blister fluid sampling, in vivo microdialysis and saliva sampling. Br J Clin Pharmacol. 1998;46:425\u201331.","journal-title":"Br J Clin Pharmacol"},{"key":"623_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7547\/14-033","volume":"105","author":"ST Housman","year":"2015","unstructured":"Housman ST, Bhalodi AA, Shepard A, Nugent J, Nicolau DP. Vancomycin tissue pharmacokinetics in patients with lower-limb infections via in vivo microdialysis. J Am Podiatr Med Assoc. 2015;105:381\u20138.","journal-title":"J Am Podiatr Med Assoc"},{"key":"623_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0195-6701(86)90007-1","volume":"7","author":"R Wise","year":"1986","unstructured":"Wise R, Donovan IA, McNulty CAM, Waldron R, Andrews JM. Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration. J Hosp Infect. 1986;7:47\u201355.","journal-title":"J Hosp Infect"},{"key":"623_CR47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/jac\/dkm263","volume":"60","author":"DP Nicolau","year":"2007","unstructured":"Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007;60:681\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"623_CR48","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1128\/AAC.50.2.788-790.2006","volume":"50","author":"HK Sun","year":"2006","unstructured":"Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2006;50:788\u201390.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR49","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1128\/AAC.01110-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008;52:2300\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR50","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1093\/jac\/dkw269","volume":"71","author":"P Matzneller","year":"2016","unstructured":"Matzneller P, \u00d6sterreicher Z, Reiter B, Lackner E, Stimpfl T, Zeitlinger M. Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study. J Antimicrob Chemother. 2016;71:3179\u201384.","journal-title":"J Antimicrob Chemother"},{"key":"623_CR51","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","volume":"50","author":"ME Stryjewski","year":"2006","unstructured":"Stryjewski ME, Chu VH, O\u2019Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50:862\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR52","doi-asserted-by":"publisher","first-page":"3303389-330","DOI":"10.3389\/fphar.2016.00330","volume":"7","author":"J Chuan","year":"2016","unstructured":"Chuan J, Zhang Y, He X, Zhu Y, Zhong L, Yu D, et al. Systematic review and meta-analysis of the efficacy and safety of telavancin for treatment of infectious disease: are we clearer? Front Pharmacol. 2016;7:3303389-330.","journal-title":"Front Pharmacol"},{"key":"623_CR53","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1128\/AAC.05002-14","volume":"59","author":"VH Tam","year":"2015","unstructured":"Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LD. Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother. 2015;59:2930\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR54","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1177\/0091270009337133","volume":"49","author":"SL Wong","year":"2009","unstructured":"Wong SL, S\u00f6rgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin\/tazobactam in healthy participants. J Clin Pharmacol. 2009;49:816\u201323.","journal-title":"J Clin Pharmacol"},{"key":"623_CR55","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1592\/phco.30.2.136","volume":"30","author":"SL Wong","year":"2010","unstructured":"Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010;30:136\u201343.","journal-title":"Pharmacotherapy"},{"key":"623_CR56","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1128\/AAC.03172-14","volume":"58","author":"DJ Farrell","year":"2014","unstructured":"Farrell DJ, Mendes RE, Rhomberg PR, Jones RN. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob Agents Chemother. 2014;58:5547\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.diagmicrobio.2014.12.011","volume":"81","author":"RE Mendes","year":"2015","unstructured":"Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis. 2015;81:275\u20139.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 1","key":"623_CR58","doi-asserted-by":"publisher","first-page":"i7","DOI":"10.1093\/jac\/dkt022","volume":"68","author":"GG Zhanel","year":"2013","unstructured":"Zhanel GG, Adam HJ, Baxter MR, et al. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007\u201311 study. J Antimicrob Chemother. 2013;68(Suppl 1):i7\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"623_CR59","unstructured":"Nichol KA, Adam HJ, Laing N, Weshnoweski B, Vashisht R, Baxter MR, et al. Activity of telavancin against Gram-positive cocci from CANWARD 2007\u20132013 using previously established and revised CLSI guidelines. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5\u20139 Sep 2014; Washington, DC."},{"key":"623_CR60","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.diagmicrobio.2016.11.002","volume":"87","author":"D Sweeney","year":"2017","unstructured":"Sweeney D, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 2017;87:121\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"623_CR61","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1128\/AAC.47.11.3602-3604.2003","volume":"47","author":"JL Pace","year":"2003","unstructured":"Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:3602\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"623_CR62","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/jac\/dkh156","volume":"53","author":"A King","year":"2004","unstructured":"King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother. 2004;53(5):797\u2013803. https:\/\/doi.org\/10.1093\/jac\/dkh156 .","journal-title":"J Antimicrob Chemother."},{"key":"623_CR63","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1128\/AAC.01264-06","volume":"51","author":"D Andes","year":"2007","unstructured":"Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51:1633\u201342.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR64","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1128\/AAC.41.10.2165","volume":"41","author":"F Biavasco","year":"1997","unstructured":"Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother. 1997;41:2165\u201372.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR65","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/jac\/38.4.589","volume":"38","author":"AJ Larsson","year":"1996","unstructured":"Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother. 1996;38:589\u201397.","journal-title":"J Antimicrob Chemother"},{"key":"623_CR66","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1086\/491712","volume":"42","author":"MJ Rybak","year":"2006","unstructured":"Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42:S35\u20139.","journal-title":"Clin Infect Dis"},{"key":"623_CR67","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1046\/j.1469-0691.2003.00692.x","volume":"9","author":"I Odenholt","year":"2003","unstructured":"Odenholt I, L\u00f6wdin E, Cars O. In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium. Clin Microbiol Infect. 2003;9:930\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"623_CR68","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1128\/AAC.35.6.1089","volume":"35","author":"EM Bailey","year":"1991","unstructured":"Bailey EM, Rybak MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother. 1991;35:1089\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR69","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1128\/AAC.34.10.1869","volume":"34","author":"WE Peetermans","year":"1990","unstructured":"Peetermans WE, Hoogeterp JJ, Hazekamp-Van Dokkum AM, Van Den Broek P, Mattie H. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother. 1990;34:1869\u201374.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR70","first-page":"225","volume":"13","author":"G Ravizzola","year":"1987","unstructured":"Ravizzola G, Pirali F, Foresti I, Turano A. Comparison of the in vitro antibacterial activity of teicoplanin and vancomycin against Gram-positive cocci. Drugs Exp Clin Res. 1987;13:225\u20139.","journal-title":"Drugs Exp Clin Res"},{"key":"623_CR71","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1128\/AAC.01470-06","volume":"51","author":"I Odenholt","year":"2007","unstructured":"Odenholt I, L\u00f6wdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother. 2007;51:3311\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR72","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1128\/AAC.00933-10","volume":"55","author":"AP MacGowan","year":"2011","unstructured":"MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2011;55:867\u201373.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR73","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00281-17","author":"AJ Lepak","year":"2017","unstructured":"Lepak AJ, Zhao M, Andes DR. Comparative pharmacodynamics of telavancin and vancomycin in the neutropenic murine thigh and lung infection models against Staphylococcus aureus. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00281-17 .","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR74","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","volume":"29","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275\u20139.","journal-title":"Pharmacotherapy"},{"key":"623_CR75","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1128\/AAC.01485-12","volume":"57","author":"NE Holmes","year":"2013","unstructured":"Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57:1654\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR76","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1128\/AAC.05609-11","volume":"56","author":"J Brown","year":"2012","unstructured":"Brown J, Brown K, Forrest A. Vancomycin AUC 24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother. 2012;56:634\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR77","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","volume":"43","author":"PA Moise-Broder","year":"2004","unstructured":"Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925\u201342.","journal-title":"Clin Pharmacokinet"},{"key":"623_CR78","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1128\/AAC.02127-12","volume":"57","author":"SN Leonard","year":"2013","unstructured":"Leonard SN, Supple ME, Gandhi RG, Patel MD. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57:2678\u201383.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR79","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1128\/AAC.00741-13","volume":"58","author":"T T\u00e4ngd\u00e9n","year":"2014","unstructured":"T\u00e4ngd\u00e9n T, Hickman RA, Forsberg P, Lagerb\u00e4ck P, Giske CG, Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing klebsiella pneumoniae by in vitro time\u2013kill experiments. Antimicrob Agents Chemother. 2014;58:1757\u201362.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR80","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1128\/AAC.01143-09","volume":"54","author":"G Lin","year":"2010","unstructured":"Lin G, Pankuch GA, Ednie LM, Appelbaum PC. Antistaphylococcal activities of telavancin tested alone and in combination by time\u2013kill assay. Antimicrob Agents Chemother. 2010;54:2201\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR81","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1128\/AAC.01544-08","volume":"53","author":"SN Leonard","year":"2009","unstructured":"Leonard SN, Vidaillac C, Rybak MJ. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2009;53:2928\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR82","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-016-0121-2","volume":"5","author":"J Yim","year":"2016","unstructured":"Yim J, Smith JR, Barber KE, Hallesy JA, Rybak MJ. Evaluation of pharmacodynamic interactions between telavancin and aztreonam or piperacillin\/tazobactam against Pseudomonas aeruginosa, Escherichia coli and methicillin-resistant Staphylococcus aureus. Infect Dis Ther. 2016;5:367\u201377.","journal-title":"Infect Dis Ther"},{"key":"623_CR83","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.4049\/jimmunol.1302692","volume":"192","author":"MC Greenlee-Wacker","year":"2014","unstructured":"Greenlee-Wacker MC, Rigby KM, Kobayashi SD, Porter AR, DeLeo FR, Nauseef WM. Phagocytosis of Staphylococcus aureus by human neutrophils prevents macrophage efferocytosis and induces programmed necrosis. J Immunol. 2014;192:4709\u201317.","journal-title":"J Immunol"},{"key":"623_CR84","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S8756-3282(99)00239-2","volume":"26","author":"SS Reilly","year":"2000","unstructured":"Reilly SS, Hudson MC, Kellam JF, Ramp WK. In vivo internalization of Staphylococcus aureus by embryonic chick osteoblasts. Bone. 2000;26:63\u201370.","journal-title":"Bone"},{"key":"623_CR85","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1006\/mpat.1999.0272","volume":"26","author":"JK Ellington","year":"1999","unstructured":"Ellington JK, Reilly SS, Ramp WK, Smeltzer MS, Kellam JF, Hudson MC. Mechanisms of Staphylococcus aureus invasion of cultured osteoblasts. Microb Pathog. 1999;26:317\u201323.","journal-title":"Microb Pathog"},{"issue":"6","key":"623_CR86","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2106\/00004623-200506000-00022","volume":"87","author":"M Bosse","year":"2005","unstructured":"Bosse M, Gruber H, Ramp W. Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis. A case report. J Bone Jt Surg Am. 2005;87(6):1343\u20137. https:\/\/doi.org\/10.2106\/JBJS.D.02649 .","journal-title":"J Bone Jt Surg Am."},{"key":"623_CR87","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature16057","volume":"527","author":"SM Lehar","year":"2015","unstructured":"Lehar SM, Pillow T, Xu M, et al. Novel antibody\u2013antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527:323\u20138.","journal-title":"Nature"},{"key":"623_CR88","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1128\/AAC.47.7.2283-2292.2003","volume":"47","author":"C Seral","year":"2003","unstructured":"Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. 2003;47:2283\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR89","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1128\/AAC.50.3.841-851.2006","volume":"50","author":"M Barcia-Macay","year":"2006","unstructured":"Barcia-Macay M, Seral C, Mingeot-Leclercq M-P, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother. 2006;50:841\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR90","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1469-0691.2008.02035.x","volume":"14","author":"S Lemaire","year":"2008","unstructured":"Lemaire S, Kosowska-Shick K, Julian K, Tulkens PM, Van Bambeke F, Appelbaum PC. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin Microbiol Infect. 2008;14:766\u201377.","journal-title":"Clin Microbiol Infect"},{"key":"623_CR91","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1128\/AAC.01146-08","volume":"53","author":"HA Nguyen","year":"2009","unstructured":"Nguyen HA, Denis O, Vergison A, Tulkens PM, Struelens MJ, Van Bambeke F. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations. Antimicrob Agents Chemother. 2009;53:1443\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR92","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1128\/AAC.48.8.2853-2860.2004","volume":"48","author":"F Bambeke Van","year":"2004","unstructured":"Van Bambeke F, Carryn S, Seral C, Chanteux H, Tyteca D, Mingeot-Leclercq M-P, et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother. 2004;48:2853\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"623_CR93","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/jac\/dkl424","volume":"58","author":"M Barcia-Macay","year":"2006","unstructured":"Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58:1177\u201384.","journal-title":"J Antimicrob Chemother"},{"key":"623_CR94","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/jac\/dkn120","volume":"61","author":"M Barcia-macay","year":"2008","unstructured":"Barcia-macay M, Mouaden F, Mingeot-Leclercq MP, Tulkens PM, Van bambeke F. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother. 2008;61:1288\u201394.","journal-title":"J Antimicrob Chemother"},{"key":"623_CR95","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/jac\/dkw254","volume":"71","author":"Z-K Ye","year":"2016","unstructured":"Ye Z-K, Chen Y-L, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71:3020\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"623_CR96","first-page":"284","volume":"53","author":"N Masuda","year":"2015","unstructured":"Masuda N, Maiguma T, Komoto A, Haruki Y, Sugiyama T, Kondo S, et al. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin. Int J Clin Pharmacol Ther. 2015;53:284\u201391.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"623_CR97","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1086\/653053","volume":"51","author":"RN Jones","year":"2010","unstructured":"Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S81\u20137.","journal-title":"Clin Infect Dis"},{"key":"623_CR98","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1086\/587896","volume":"46","author":"ME Stryjewski","year":"2008","unstructured":"Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis. 2008;46:1683\u201393.","journal-title":"Clin Infect Dis"},{"key":"623_CR99","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/cid\/ciq031","volume":"52","author":"E Rubinstein","year":"2011","unstructured":"Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52:31\u201340.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"623_CR100","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40121-017-0162-1","volume":"6","author":"SE Wilson","year":"2017","unstructured":"Wilson SE, Graham DR, Wang W, Bruss JB, Castaneda-Ruiz B. Telavancin in the treatment of concurrent Staphylococcus aureus bacteremia: a retrospective analysis of ATLAS and ATTAIN studies. Infect Dis Ther. 2017;6(3):413\u201322. https:\/\/doi.org\/10.1007\/s40121-017-0162-1 .","journal-title":"Infect Dis Ther."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0623-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T16:02:42Z","timestamp":1603641762000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0623-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,13]]},"references-count":100,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0623-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,13]]},"assertion":[{"value":"13 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist with the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Zeitlinger and Dr. al Jalali have no conflicts of interest that are relevant to the content of this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}